The Phil Mickelson Enbrel Campaign

From the Audition in the Press to TV, Web, and Print Advertising. Pfizer and Amgen demonstrate how to launch a branded spokesperson campaign starting from a bit of over-the-top unregulated press relations to fully regulated TV, print, and Web advertising. It must be costing a mint!

Checking Under the Hood of Pharma Mobile Apps

Let's look 'under the hoods' of two pharma-sponsored mobile apps and compare disclaimers. We'll compare Janssen's PASI calculator, which has an update disclaimer, with the new AFib Educator 2.0 app developed by Sanofi-Aventis.

Fair Social Media Practice Principles

Rules for Third-Party Engagement in Patient/Physician Social Networks. A Social Media Policy is not just an agreement that users must abide by. More importantly, it is a PROMISE to users from site owners/sponsors concerning how they will protect or attempt to protect user-generated content, personal conversations, interactions, and engagements with third-parties on the site. These policies should comply with as-yet-to-be-determined, universally accepted 'fair social media practice principles.'

Pfizer, Show Us Your Social Media “Playbook”

Has It Been Found? What Does It Reveal About Pfizer's Social Media Implementation Plan?. Ray Kerins (@raykerins), Vice President of Worldwide Communications at Pfizer, talks about Pfizer's 'groundbreaking internal Social Media Playbook' but won't show it to us. What can be in the playbook? How many people does Pfizer dedicate to social media? This article discusses those questions and offers a peek into a playbook contender.

Proposed Rules for Physician Payment Sunshine Act

Looming Challenges Cloud Implementation. This article reviews the strategic implications of the Sunshine Act and also presents highlights of the draft regulations rule released by the Centers for Medicare and Medicaid Services on December 15, 2011.

Pharma TeleWeb e-Detailing

This article summarizes Eli Lilly's European experience using TeleWeb e-detailing, which combines a personal sales rep phone call with Web site surfing.

Limiting Bias in Commercially Supported CME

Many critics of pharma-supported CME believe this support leads to bias. Between 9 May 2011 and 13 September 2011, readers of Pharma Marketing News were asked to answer a few short questions relating to potential bias in industry-supported CME programs and how to limit the need for industry funding of CME. The results are summarized in this article.

Double Dip in DTC Ad Spend!

Direct-to-Consumer (DTC) pharmaceutical advertising spending suffered a 'double dip' recession between 2007 and 2010, according to data presented in the AdAge Insights Whitepaper

Physicians Are Concerned About Pharma Support of CME, But Are Unwilling to Pay Their...

Talk about having your cake and eating it too! Commercial funding of continuing medical education (CME) and the potential for bias appear to concern many physicians, yet only a TINY MINORITY (7%) are willing to pay registration fees to eliminate or offset commercial funding sources, according to a report in the May 9, 2011, issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

Pfizer Battles to Protect Lipitor Cash Cow

Lipitor Won't Go Gentle Into that Good Generic Night. Pfizer is taking a number of steps to protect it's Lipitor franchise and it hopes that many patients currently taking Lipitor will remain loyal to the brand.
- Advertisement -